Driven by a philosophy of continuous scientific evolution and patient-centered diagnostic care, Hycor Biomedical is committed to advancing in vitro diagnostic innovation that adapts to the ever-changing global healthcare ecosystem. Rooted in the belief that precision is the foundation of effective medicine, Hycor focuses on improving the quality of human life through modern, responsive, and highly automated diagnostic solutions. Its approach emphasizes technological agility, state-of-the-art microparticle chemistry, and long-term value creation in clinical laboratories, ensuring that allergy and autoimmune testing developments align with real-world clinician and patient needs. Through this commitment, Hycor Biomedical contributes to enhancing access to meaningful diagnostic innovations that support faster, more accurate treatment outcomes and improved quality of life across global markets.
Advanced healthcare innovation and high-precision clinical diagnostics form a key part of Arcade Pharma’s expanding healthcare portfolio. Since becoming operational in 2020, Arcade Pharma has strengthened its global partnerships by collaborating with Hycor Biomedical to introduce forward-thinking, patient-centric diagnostic philosophies and innovative immunodiagnostic approaches to the Sri Lankan market.
Our healthcare portfolio focuses on delivering next-generation solutions that evolve with the changing medical ecosystem, supporting improved quality of life and better patient outcomes. By integrating automated innovation, scientific advancement, and modern diagnostic thinking, we ensure access to reliable and meaningful diagnostic solutions for healthcare professionals, hospitals, and clinical laboratories.
Through its strategic partnership with Hycor Biomedical, Arcade Pharma continues to expand access to progressive and sustainable allergy and autoimmune testing innovation, reinforcing its commitment to improving human life and supporting the future of global healthcare.
High-quality in vitro diagnostic solutions across allergy and autoimmune testing, developed through specialized in-house innovation and state-of-the-art manufacturing models to serve clinical laboratories worldwide.
Comprehensive regulatory compliance, laboratory channel distribution, and commercial support tailored for global healthcare markets, optimizing regional availability of advanced immunoassay platforms and reagents.
Innovative paramagnetic, streptavidin-coated microparticle systems engineered to provide vast reaction surfaces, dramatically reducing required patient sample volumes while maximizing test sensitivity.
Scientifically advanced, liquid ready-to-use reagents designed to eliminate common assay interferences and sample matrix anomalies, ensuring exceptional accuracy and consistent test reproducibility.
High-throughput clinical instruments—such as the NOVEOS analyzer—utilizing proprietary dual-technology optics to seamlessly integrate chemiluminescence and fluorescence for streamlined laboratory efficiency.
A comprehensive menu of FDA-cleared and WHO-traceable allergen reagents formulated to deliver quantitative measurement of total and specific IgE for precise clinical diagnosis.
Patient-friendly diagnostics utilizing breakthrough low-volume sampling technology—requiring as little as 4 µL per test—specifically designed to relieve patient burden during vulnerable blood collection processes.
Advanced automated enzyme immunoassay solutions utilizing premium solid-phase and crystalline tracking technologies to systematically identify antibodies and support early clinical detection of complex autoimmune disorders.
Hycor Biomedical is a global pioneer in in vitro diagnostics, built on a philosophy of continuous scientific evolution and precision within the clinical laboratory ecosystem. Guided by the belief that accuracy and efficiency are the foundations of effective patient care, Hycor focuses on advancing human health through high-precision, automated immunodiagnostic systems that continuously respond to changing medical and testing needs. The company emphasizes patient-centric diagnostics, microparticle technology, and sustainable laboratory improvement to enhance overall quality of life. Through its commitment to innovation and laboratory automation, Hycor Biomedical contributes to the development of modern testing solutions that support faster, more reliable patient outcomes and long-term diagnostic system improvement. Through its strategic partnership with Arcade Pharma, these progressive diagnostic concepts and solutions are aligned with Sri Lanka’s healthcare sector, strengthening access to innovative and high-precision allergy and autoimmune testing thinking.
Contact Arcade Pharma for product information, partnership opportunities, and diagnostic collaboration inquiries related to Hycor Biomedical’s automated and patient-centric allergy and autoimmune testing portfolio.